Last Updated : October 17, 2024
Details
Generic Name:
belzutifan
Project Status:
Pending
Therapeutic Area:
advanced renal cell carcinoma (RCC)
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Welireg
Project Line:
Reimbursement Review
Project Number:
PC0386-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Welireg for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies.
Fee Schedule:
Pending
Indications:
Welireg for the treatment of adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 17, 2024